The continuous adverse impact of COVID-19 on temporomandibular disorders and bruxism: comparison of pre- during- and post-pandemic time periods.


Journal

BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684

Informations de publication

Date de publication:
04 10 2023
Historique:
received: 16 05 2023
accepted: 23 09 2023
medline: 6 10 2023
pubmed: 5 10 2023
entrez: 4 10 2023
Statut: epublish

Résumé

Some of the conditions affected by the COVID-19 pandemic were Temporomandibular Disorders (TMD) and bruxism. The present study compares the effect of the pandemic on TMD and bruxism (sleep and awake) in three time periods: before the pandemic (pre-COV), during the pandemic (during-COV) and after the pandemic subsided (post-COVR). A total of 587 adult patients (108 in the pre-COV group, 180 in the during-COV group and 252 in the post-COVR group) who arrived for a routine dental treatment between October 2018 and January 2023 were evaluated according to Axis I diagnosis of the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). Each patient received a DC/TMD Axis I diagnosis as follows: (i) Painful TMD (defined by the presence of at least one of the following - local myalgia, myofascial pain with referral, arthralgia or headache attributed to TMD); (ii) Non painful TMD (defined by the presence of disc displacement with/without reduction, degenerative joint disorders and/or dislocation), (iii) Possible sleep bruxism (SB) and/or (iv) Possible awake bruxism (AB). Logistic regression analyses were conducted to establish the impact of time and gender on the prospects of painful TMD, non-painful TMD, SB and AB. The odds of subjects to be diagnosed with painful TMD at the post-COVR era were 3.3 times higher compared to the pre-pandemic time period (pre-COV, 95% C.I. 1.438-7.585). The odds of subjects to be diagnosed with non-painful TMD during-COV were 4 times higher compared to the pre-COV era (95% C.I. 1.332-12.542). The odds of subjects to present possible SB at post-COVR were 2.7 times higher compared to pre-pandemic (pre-COV, 95% C.I. 1.258-5.889, p < 0.05) and the odds to present possible AB after the pandemic subsided (post-COVR) were 3.2 times compared to the pre-pandemic period (95% C.I. 1.496-6.949). The odds of female subjects to be diagnosed with either painful or non-painful TMD were 3.7-4.4 times higher, compared to males. Results indicate that with regard to TMD and bruxism the pandemic adverse effects persist also after COVID-19 subsides and the restrictions caused by it are abolished. Apparently, during the pandemic females were affected more seriously by painful and non-painful TMD than males.

Identifiants

pubmed: 37794398
doi: 10.1186/s12903-023-03447-4
pii: 10.1186/s12903-023-03447-4
pmc: PMC10552226
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

716

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

J Appl Oral Sci. 2020;28:e20200263
pubmed: 32401942
J Oral Rehabil. 2019 Sep;46(9):845-861
pubmed: 31090938
Head Face Med. 2008 Feb 28;4:4
pubmed: 18307774
J Oral Facial Pain Headache. 2018 Spring;32(2):137-150
pubmed: 29694464
Brain Sci. 2023 Mar 12;13(3):
pubmed: 36979291
J Clin Med. 2021 Apr 08;10(8):
pubmed: 33918017
Crit Rev Oral Biol Med. 1997;8(3):291-305
pubmed: 9260045
Cranio. 2021 Oct 15;:1-6
pubmed: 34652252
Oral Dis. 2016 Oct;22(7):609-19
pubmed: 26704694
Pain. 2011 Mar;152(3 Suppl):S2-S15
pubmed: 20961685
Biol Sex Differ. 2020 Oct 13;11(1):56
pubmed: 33050941
J Dent Res. 2016 Sep;95(10):1084-92
pubmed: 27339423
J Clin Med. 2023 Apr 02;12(7):
pubmed: 37048735
J Clin Med. 2020 Oct 12;9(10):
pubmed: 33053640
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
J Pain. 2011 Nov;12(11 Suppl):T4-11.e1-2
pubmed: 22074751
J Neurosci Rural Pract. 2020 Oct;11(4):519-525
pubmed: 33144785
Global Health. 2020 Jul 6;16(1):57
pubmed: 32631403
J Oral Rehabil. 2023 Jan 3;:
pubmed: 36597658
JDR Clin Trans Res. 2023 Apr 21;:23800844231165016
pubmed: 37082861
J Oral Rehabil. 2018 Nov;45(11):837-844
pubmed: 29926505
J Oral Rehabil. 2023 Aug;50(8):706-714
pubmed: 37078711
Clin Oral Investig. 2021 Feb;25(2):441-453
pubmed: 33409693
Int J Mol Sci. 2022 Oct 12;23(20):
pubmed: 36293017
J Oral Rehabil. 2010 Mar;37(3):157-62
pubmed: 20002533
J Dent. 2021 Aug;111:103711
pubmed: 34090993
J Oral Rehabil. 2018 Nov;45(11):881-889
pubmed: 29972707
Pain Res Manag. 2018 May 2;2018:7020751
pubmed: 29854038
Psychol Med. 2021 Apr;51(6):881-893
pubmed: 33648613
J Dent Hyg. 2013 Apr;87(2):73-81
pubmed: 23986140
Cephalalgia. 2017 Jun;37(7):692-704
pubmed: 28068790
J Oral Facial Pain Headache. 2020 Fall;34(4):379-397
pubmed: 33290444
J Affect Disord. 2022 Aug 1;310:384-395
pubmed: 35561885
J Oral Facial Pain Headache. 2016 Summer;30(3):249-54
pubmed: 27472528
BMC Oral Health. 2023 Apr 28;23(1):248
pubmed: 37118748
J Oral Rehabil. 2010 Aug;37(8):624-40
pubmed: 20236235
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
Lasers Med Sci. 2020 Feb;35(1):181-192
pubmed: 31396794
J Clin Med. 2019 Aug 29;8(9):
pubmed: 31470624
J Oral Rehabil. 2023 Sep;50(9):822-829
pubmed: 37073471
J Clin Med. 2022 Jan 25;11(3):
pubmed: 35160041
Front Neurol. 2020 Dec 09;11:564431
pubmed: 33362686
J Dent Res. 2002 Apr;81(4):284-8
pubmed: 12097315
Int J Environ Res Public Health. 2023 Jan 30;20(3):
pubmed: 36767818
Ind Psychiatry J. 2011 Jan;20(1):4-10
pubmed: 22969173
Sleep Med Rev. 2022 Apr;62:101591
pubmed: 35131664
Clin J Pain. 2013 Aug;29(8):712-6
pubmed: 23343773
J Pers Med. 2022 Aug 07;12(8):
pubmed: 36013244

Auteurs

Tamar Shalev-Antsel (T)

Department of Oral Rehabilitation, The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Orit Winocur-Arias (O)

Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Pessia Friedman-Rubin (P)

Department of Oral Rehabilitation, The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Guy Naim (G)

The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Lihi Keren (L)

The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Ilana Eli (I)

The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel.

Alona Emodi-Perlman (A)

Department of Oral Rehabilitation, The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6139001, Israel. dr.emodi@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH